Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Projected CAGR for the Neurogenetic Testing Market Size from 2025 to 2034?
The market size for neurogenetic testing has experienced swift expansion in the last few years, escalating from a worth of $0.61 billion in 2024 to a projected worth of $0.7 billion in 2025, indicating a compound annual growth rate (CAGR) of 13.5%. The notable growth observed in the past era is largely due to a surge in neurological disease occurrences, enhanced life science research, increasing instances of Parkinson’s disease, a rise in cancer incidents, and heightened knowledge among healthcare experts.
The market size for neurogenetic testing is projected to experience swift expansion over the next few years, achieving a value of$1.12 billion in 2029, growing at a compound annual growth rate (CAGR) of 12.7%. The escalation expected during this forecast period is credited to the extended use in personalized medicine, an increase in chronic diseases, a surge in the establishment of hospitals and diagnostic laboratories, and the growing necessity for early disease detection. Key trends for the predicted period encompass technological progress, an increased preference for non-invasive testing procedures, the introduction of new products, strategic partnerships, and the discovery of novel biomarkers associated with neurological conditions.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Neurogenetic Testing Market?
The increase in occurrences of neurological disorders is anticipated to boost the expansion of the neurogenetic testing market. These neurological disorders involve conditions that impact the nervous system, encompassing the brain, spinal cord, and nerves. Genetic predisposition, infections, trauma, toxins, autoimmune responses and degeneration contribute to the prevalence of these disorders. Neurogenetic testing notably improves the identification, treatment, and management of such disorders by providing personalized insights into genetic risk factors. It also helps in directing treatment decisions, and enabling individuals and families to make knowledgeable health care choices, thereby enhancing patient care and outcomes. For example, as per the European Brain Council, a non-profit organization based in Belgium, in April 2022, over 600 neurological diseases and around 300 psychiatric conditions affect millions worldwide, including those suffering from epilepsy, which is approximately 65 million. In Europe, about 10.5 million people are afflicted with dementia, with estimates suggesting an increase to 18.7 million by 2050. As a result of these factors, the increasing prevalence of neurological disorders is anticipated to propel the growth of the neurogenetic testing market.
Which Key Market Segments Comprise the Neurogenetic Testing Market and Drive Its Revenue Growth?
The neurogenetic testingmarket covered in this report is segmented –
1) By Type: Microarray Analysis; Whole-Exome Sequencing (WES); Multiplex Ligation Dependent Probe Amplification (MLPA); Polymerase Chain Reaction (PCR) Tests; Other Types
2) By Disease: Rare Genetic Disorder; Cancer; Cystic Fibrosis; Sickle Cell Anemia; Duchenne Muscular Dystrophy; Thalassemia; Huntington’s Disease; Fragile X Syndrome; Other Diseases
3) By End-Users: Hospitals; Specialty Clinics; Research Institutes; Diagnostics Laboratories
Subsegments:
1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray; Single Nucleotide Polymorphism (SNP) Microarray; Gene Expression Microarray
2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing; Clinical Exome Sequencing; Research-Grade Exome Sequencing
3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation; MLPA For Methylation Analysis; MLPA For Specific Disease Detection
4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR); Reverse Transcription PCR (RT-PCR); Digital PCR (dPCR)
5) By Other Types: Next-Generation Sequencing (NGS); Southern Blotting; Fluorescence In Situ Hybridization (FISH); Sanger Sequencing
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=16131&type=smp
Which Areas Are Leading Regions in the Neurogenetic Testing Market Expansion Across the Globe?
North America was the largest region in the neurogenetic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in theNeurogenetic Testing Market Over the Coming Years?
Key players in the neurogenetic testing market, such as Nucleus Genomics, are introducing pioneering products like whole-genome sequencing, to improve the precision and range of genetic studies. This allows for more thorough and personalized tests for neurological issues. Whole-genome sequencing (WGS), a cutting-edge technique for genetic testing, involves determining the complete DNA sequence of a person’s genome. Nucleus Genomics, a US-based genetic analysis provider, introduced a DNA analysis product in March 2024. This platform works towards giving people in-depth awareness of their genetic proclivities, thus enabling informed choices about their health. Possessing advanced technology and expert genetic counseling services, Nucleus Genomics aims to transform the genetic testing landscape by making whole-genome sequencing accessible to everybody, thereby bringing about a significant shift in genomic medicine.
View the full report here:
https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report
How Is the Neurogenetic Testing Market Conceptually Defined?
Neurogenetic testing is a type of genetic testing that focuses on identifying genetic variations associated with neurological disorders or conditions affecting the nervous system. It is used for diagnosing, predicting, and managing neurological disorders, as well as facilitating research and the development of personalized treatment approaches in the field of neurology and genetics.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16131
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model